Legalization of Cannabis in Canada a Major Win for the Sector

HENDERSON, NV / ACCESSWIRE / July 9, 2018 / As a result of Canada's push for legalization, their stock exchanges has seen a flurry of cross-listing activity from companies eager to snap up investment capital and carve out dominant positions in a growing global Cannabis market. Marijuana producers that operate in U.S. states where pot is legal are prevented from public listings in their home country because the drug is prohibited at the federal level, so they turn their focus north for a legal avenue to raise public capital.

More recently, several medical marijuana companies that operate solely in Canada, and are able to list in the United States because the drug is legal for medicinal use in their home jurisdictions, have listed or announced intentions to go public in the U.S. in order to tap a bigger pool of investors.

There is plenty of room for optimism with the projected market share in the global legal cannabis industry projecting about $57B a year in spending.

These cannabis related companies could benefit tremendously from legalization in Canada: Nightfood Hldgs Inc. (NGTF), GW Pharmaceuticals (GWPH), Insys Therapeutics Inc. (INSY), CV Sciences, Inc. (CVSI), Cronos Group (CRON)

Nightfood Hldgs Inc. (NGTF)

Market Cap: $15.7M, current share price: $.41

NightFood Holdings, Inc. is the first, and currently only, company to address the $50+ Billion dollar consumer spend in the night time snack category. NightFood manufactures and distributes better-for-you snacks specifically formulated to satisfy unhealthy nighttime cravings in a better, healthier, more sleep-friendly way. In addition, the Company recently created a new subsidiary, MJ Munchies, Inc., under which it will pursue snack and other consumer-facing opportunities within the growing marijuana and cannabis sectors. The company released an 8-K on July 5th, 2018 that stated "The Registrant successfully obtained the rights to the United States Registered Trademark of "The Half-Baked Cookie Company", Registration Number 4,424,408. This action was taken in direct response to comments by the United States Patent & Trademark Office that the possibility existed for confusion in the marketplace between snacks bearing the "Half-Baked" trademark for which MJ Munchies, Inc. had recently applied, and the existing Half-Baked Cookie Company trademark. The concern about possible confusion between these two marks was the only reason given by the USPTO for not previously issuing the registration for "Half-Baked". Since the Registrant has now acquired the Trademark that was cited as one that might cause confusion in the marketplace, it is expected that the final approval will be issued by the USPTO shortly."

GW Pharmaceuticals (GWPH)

Market Cap: $4.22B, current share price: $139.66

GW Pharmaceuticals plc, is a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia.

Insys Therapeutics Inc. (INSY)

Market Cap: $521.82M, current share price: $7.07

Insys Therapeutics, Inc., is a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain.

CV Sciences, Inc. (CVSI)

Market Cap: 150.49M, current share price: $1.55

CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction.

Cronos Group Inc. (CRON)

Market Cap: 1.23B, current share price: $7.00

Cronos Group Inc. is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (MMPR). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty-four thousand total by Regal Consulting, LLC, for NGTF. NGTF and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article's distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC